349 related articles for article (PubMed ID: 32759756)
1. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection.
van den Berg F; Limani SW; Mnyandu N; Maepa MB; Ely A; Arbuthnot P
Viruses; 2020 Aug; 12(8):. PubMed ID: 32759756
[TBL] [Abstract][Full Text] [Related]
2. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs.
Mowa MB; Crowther C; Ely A; Arbuthnot P
Microrna; 2012; 1(1):19-25. PubMed ID: 25048086
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 for hepatitis B virus infection treatment.
Cai B; Chang S; Tian Y; Zhen S
Immun Inflamm Dis; 2023 May; 11(5):e866. PubMed ID: 37249290
[TBL] [Abstract][Full Text] [Related]
4. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus.
Ely A; Arbuthnot P
Discov Med; 2015 Sep; 20(109):137-43. PubMed ID: 26463095
[TBL] [Abstract][Full Text] [Related]
5. HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA.
Yan Z; Zeng J; Yu Y; Xiang K; Hu H; Zhou X; Gu L; Wang L; Zhao J; Young JAT; Gao L
J Hepatol; 2017 Jun; 66(6):1149-1157. PubMed ID: 28213165
[TBL] [Abstract][Full Text] [Related]
6. Revisiting Hepatitis B Virus: Challenges of Curative Therapies.
Hu J; Protzer U; Siddiqui A
J Virol; 2019 Oct; 93(20):. PubMed ID: 31375584
[TBL] [Abstract][Full Text] [Related]
7. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.
Laras A; Koskinas J; Dimou E; Kostamena A; Hadziyannis SJ
Hepatology; 2006 Sep; 44(3):694-702. PubMed ID: 16941694
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector.
Mnyandu N; Arbuthnot P; Maepa MB
Methods Mol Biol; 2020; 2115():171-183. PubMed ID: 32006401
[TBL] [Abstract][Full Text] [Related]
9. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation.
Zhang W; Chen J; Wu M; Zhang X; Zhang M; Yue L; Li Y; Liu J; Li B; Shen F; Wang Y; Bai L; Protzer U; Levrero M; Yuan Z
Hepatology; 2017 Aug; 66(2):398-415. PubMed ID: 28236308
[TBL] [Abstract][Full Text] [Related]
10. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
[TBL] [Abstract][Full Text] [Related]
11. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals.
Huang H; Wang J; Li W; Chen R; Chen X; Zhang F; Xu D; Lu F
J Clin Virol; 2018; 99-100():71-78. PubMed ID: 29353073
[TBL] [Abstract][Full Text] [Related]
12. SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases.
Ren JH; Hu JL; Cheng ST; Yu HB; Wong VKW; Law BYK; Yang YF; Huang Y; Liu Y; Chen WX; Cai XF; Tang H; Hu Y; Zhang WL; Liu X; Long QX; Zhou L; Tao NN; Zhou HZ; Yang QX; Ren F; He L; Gong R; Huang AL; Chen J
Hepatology; 2018 Oct; 68(4):1260-1276. PubMed ID: 29624717
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation.
Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J
mBio; 2020 Feb; 11(1):. PubMed ID: 32071277
[TBL] [Abstract][Full Text] [Related]
14. Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure.
Lucifora J; Protzer U
J Hepatol; 2016 Apr; 64(1 Suppl):S41-S48. PubMed ID: 27084036
[TBL] [Abstract][Full Text] [Related]
15. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Sheraz M; Cheng J; Tang L; Chang J; Guo JT
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Gene Therapy Coming to Age.
Soriano V
AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
[TBL] [Abstract][Full Text] [Related]
17. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
Sun Y; Li Z; Li L; Li J; Liu X; Li W
Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA.
Sekiba K; Otsuka M; Ohno M; Yamagami M; Kishikawa T; Suzuki T; Ishibashi R; Seimiya T; Tanaka E; Koike K
World J Gastroenterol; 2018 Jun; 24(21):2261-2268. PubMed ID: 29881235
[TBL] [Abstract][Full Text] [Related]
20. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
